Elorac Reports Impressive Results for Scalp Psoriasis Shampoo Trial

Preliminary results of a nationwide, patient-centered outcome trial for Zithranol® Shampoo (anthralin 1%, microcrystalline-encapsulated system) showed that 88% of 41 patients with treatment-resistant scalp psoriasis demonstrated improvement in their scalp disease.

VERNON HILLS, Ill.--()--Elorac, Inc. released preliminary results today of their patient-centered Experience Zithranol Shampoo (EZ) Trial. The EZ Trial was designed to collect “real life” data based on patients’ assessment of their experience before and after using the product. After using Zithranol Shampoo from 14-30 days, 93% of patients reported that they would use Zithranol Shampoo again.

Select dermatology offices throughout the country identified patients with scalp psoriasis that had been resistant to standard therapies. Patients were provided Zithranol Shampoo therapy with other documents including a data collection form for them to assess their scalp psoriasis before and after treatment.

Zithranol Shampoo is designed to fit into any scalp psoriasis treatment regimen since it is a true shampoo which only needs to be left on a few minutes before rinsing away.

Highlights of the EZ Trial include:

  • 88% of patients observed visible improvement on their scalp.
  • 96% of patients with severe scalp psoriasis improved to a classification ranging from “moderate” to “barely visible”.
  • 93% of patients found Zithranol Shampoo easy to use.
  • 8 days was the average length of time for patients to see results.

“Psoriasis patients are typically very sensitive to the state of their condition and how treatments work for them,” observed dermatologist Scott B. Phillips, M.D., Senior Vice President, Scientific Affairs. “A patient-driven trial, such as this, provides a good picture of how treatment works in everyday life.”

Zithranol Shampoo is steroid-free and harnesses the power and safety of anthralin in an advanced delivery system using microcrystalline encapsulation. It can be safely used long term and in combination with other psoriasis products.

“Our unique formulation gently treats psoriatic lesions while moisturizing the scalp,” said Christopher Gabanski, Chief Commercial Officer. “Zithranol Shampoo combines the latest technology in microencapsulation and co-surfactant emollients to deliver anthralin directly to the targeted plaques.”

Zithranol Shampoo is available by prescription at pharmacies nationwide. There are no branded or generic equivalents.

For full prescribing information and patient instructions regarding Zithranol Shampoo, please visit www.eloracpharma.com.

About Elorac

Elorac, Inc. is a privately owned, specialty pharmaceutical company engaged in the development and commercialization of novel products for dermatology, allergy and oncology. The Company markets dermatological products in the United States through its dedicated internal sales force. Elorac has a robust pipeline of products in development, including naloxone lotion, a product that has received orphan drug and fast-track designations from the U.S. Food and Drug Administration for treatment of pruritus accompanying cutaneous T-cell lymphoma, and cidoxepin, a product that is being developed for chronic urticaria. According to Inc. magazine’s 2013 list of fastest-growing private U.S. companies, Elorac ranked 23rd among health-care companies and No. 1 among pharmaceutical companies.

About Psoriasis

Psoriasis is a non-contagious, chronic skin disease that affects approximately 7.5 million Americans according to the National Institutes of Health (NIH). It usually appears as thick, red, scaly patches created by a rapid overgrowth of skin cells. Patient support for psoriasis and more information about the condition can be found on the National Psoriasis Foundation’s website, www.psoriasis.org.

Contacts

Elorac, Inc.
Rhonda Pavicich, Senior Director of Marketing
847-362-8200 ext. 228
rpavicich@eloracpharma.com

Sharing

Contacts

Elorac, Inc.
Rhonda Pavicich, Senior Director of Marketing
847-362-8200 ext. 228
rpavicich@eloracpharma.com